Public Release: 

Proton pump inhibitors do not interfere with benefit of antiplatelet drugs clopidogrel or prasugrel in patients after an acute coronary syndrome

Lancet

Proton pump inhibitors (PPIs--a commonly prescribed antacid medication) do not interfere with the clinical benefit of the anticlotting drugs clopidogrel or prasugrel (thienopyridines) in patients after an acute coronary syndrome (heart attack or unstable angina). These findings are in contrast to other recent studies that have shown potential harm when these two classes of drugs are combined. The results are published in an Article Online First and in an upcoming edition of the Lancet, written by Dr Michelle O'Donoghue, Brigham and Women's Hospital, Boston, MA, USA, and colleagues.

PPIs are often administered with clopidogrel and prasugrel, to help reduce the risk of gastrointestinal bleeding, a strategy that is endorsed by existing guidelines. But several studies have raised concerns that PPIs could negate the clinical benefit of clopidogrel. The authors studied the effects of PPIs in the TRITON-TIMI 38 trial, and one other, smaller trial. TRITON-TIMI 38 enrolled 13608 patients after a heart attack or unstable angina and randomly assigned them to clopidogrel or prasugrel. Use of a PPI in combination with these drugs did not increase the risk of cardiovascular events, including death, heart attack, or stroke.

The authors conclude: "The current findings do not support the need to avoid concomitant use of proton pump inhibitors, when clinically indicated, in patients receiving clopidogrel or prasugrel."

In an accompanying Comment, Dr Dirk Sibbing and Dr Adnan Kastrati, Technische Universität München, Munich, Germany, agree that patients with a risk profile similar to those patients in the TRITON-TIMI 38 study can be safely treated with a proton pump inhibitor on top of clopidogrel or prasugrel. They say: "Caution is however required when prescribing proton pump inhibitors in selected high risk patients with intrinsic reduced response to thienopyridines."

###

Dr Michelle O'Donoghue, TIMI Study Group, Brigham and Women's Hospital, Boston, MA, USA T) +1617 278-0145 E) modonoghue@partners.org

Dr Dirk Sibbing, Technische Universität München, Munich, Germany. T) +49-173-6674477 E) dirk@sibbing.net

For full Article and Comment, see: http://press.thelancet.com/escppi.pdf

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.